ArticleResearch square2026
Defining a glycemic persistence index (GPI) for continuous glucose monitoring.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Sustained hyperglycemia is the core driver of diabetes complications. Continuous glucose monitoring (CGM) provides rich temporal glucose data, but effective summarization that integrates both magnitude and duration of sustained hyperglycemia into a single and paramter-free scalar remains challenging. We introduce the glycemic persistence index (GPI), a simple, threshold-free CGM-derived metric defined as the largest integer k such that at least k minutes are spent at glucose levels ≥ k mg/dL within a day. For example, a GPI of 125 means that glucose levels were ≥ 125 mg/dL for at least 125 minutes during that day. Geometrically, after ranking glucose values in decreasing order, GPI is given by the intersection at which glucose level and cumulative duration take the same value. Using CGM data from the International Diabetes Closed Loop randomized trial (168 adults with type 1 diabetes), GPI sensitively captured closed-loop treatment benefit with significantly lower values in the closed-loop group compared with sensor-augmented pump therapy (P = 0.0001). GPI correlated with HbA1c and daily mean glucose, while distinguishing patterns of sustained hyperglycemia among individuals with similar conventional metrics. As a simple, device-independent, and threshold-free scalar, GPI quantifies hyperglycemia by jointly capturing its magnitude and duration, enabling consistent and intuitive glycemic profiling accessible to both specialists and non-specialists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.